Anthony Parravani, MD
Nephrology · Morgantown, WVNPI 1053536409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $139 of the $166 with a category attached, or 83.6%. 6 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 31.4% of the total. Reporting peaked in 2022 at $68 and has fallen 52.3% since, to $32 in 2024. That places this record below the midpoint for nephrology clinicians in WV, where the typical reported total is $740.
Across 12 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$52
- Nxstage Medical, Inc.$45
- Fresenius USA Marketing, Inc.$22
- Outset Medical Inc$20
- Calliditas Therapeutics US Inc.$14
- Travere Therapeutics, Inc.$14
Across 25 payments — averaging $4080.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$102K
What the payments were for
- Food & beverage$13984%
- Education$2716%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Nxstage Medical, Inc. | 2 | $45 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Outset Medical Inc | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 4 | $14 |
How this compares
$166 in reported general payments places this provider in the 25th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $30,897 |
| Potassium Citrate ErPotassium Citrate | 63 | $7,841 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $3,542 |
| Nifedipine ErNifedipine | 80 | $3,200 |
| Bumetanide | 25 | $2,735 |
| Chlorthalidone | 134 | $2,651 |
| Tacrolimus | 26 | $2,463 |
| Sevelamer Carbonate | 30 | $2,010 |
| Potassium Chloride | 30 | $1,882 |
| Calcitriol | 88 | $1,841 |
| Losartan Potassium | 78 | $947 |
| Labetalol Hcl | 26 | $874 |
| Torsemide | 48 | $757 |
| Tamsulosin Hcl | 47 | $484 |
| Klor-Con M20Potassium Chloride | 12 | $453 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Morgantown
- Arijit ChakravartyMorgantown$19K
- Rebecca SchmidtMorgantown$5K
- Adeem AkbarMorgantown$740
- Anas DiabMorgantown$482
- Bethany PellegrinoMorgantown$160
- Jennifer BergeronMorgantown$124
- Dinesh Kumar KannabhiranMorgantown$117
- Vijay VidyasagarMorgantown$40
- Sana AkbarMorgantown$34
- Mark PolingMorgantown$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.